← 返回前沿论文

CORT 沉默损害迁移和侵袭:基于糖基化的风险模型(CORT/LPAR5/CEBPA/MYH10/MAGEA11)在骨肉瘤中的验证

英文原题:CORT silencing impairs migration and invasion: validation of a glycosylation-based risk model (CORT/LPAR5/CEBPA/MYH10/MAGEA11) in osteosarcoma.

查看英文原题

CORT silencing impairs migration and invasion: validation of a glycosylation-based risk model (CORT/LPAR5/CEBPA/MYH10/MAGEA11) in osteosarcoma.

PubMed 2026/01/05(内容时间) Eur J Med Res Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们开发了一个有用的风险模型,本研究为 OS 治疗提供了新的见解。

研究思路结论见上方概要

骨肉瘤(OS)是一种青少年中预后较差的骨恶性肿瘤。我们旨在探索OS中与糖基化相关的特征。

从TARGET数据库中获取了185个糖基化相关基因(GRGs)和RNA-seq数据。基于显著的预后因素,应用ConsensusClusterPlus包进行各种亚型分析。随后,limma R包对RiskScore模型进行了Lasso分析。survminer包进行了Kaplan-Meier(KM)分析,timeROC包用于分类器效率评估。此外,ssGSEA方法和MCPcounter进行了免疫浸润分析。最后,通过PCR、伤口愈合和transwell实验分别评估了所选关键基因的表达及其迁移和侵袭能力。

高 GRG 评分与不良预后相关。基于预后 GRG 的无监督聚类识别出两个亚型(C1/C2),其中 C1 表现出更差的结局。由亚型特异性差异表达基因构建了包含 CORT、LPAR5、CEBPA、MYH10 和 MAGEA11 的预后 RiskScore 模型。该模型在训练队列和验证队列中均有效地将患者分为高风险组和低风险组,高风险患者的生存期显著更短。RiskScore 是一个独立预后因素,高风险组患者中观察到巨噬细胞和 NK 细胞等细胞的浸润水平较低。在外部免疫治疗队列中,高风险患者的生存和治疗反应更差。在功能上,沉默关键模型基因 CORT 可在体外损害骨肉瘤细胞的迁移和侵袭。

展开英文摘要原文

Osteosarcoma (OS) is a bone malignancy among adolescents with a poor prognosis. We aimed to explore the glycosylation-related features in OS.

A sum of 185 glycosylation-related genes (GRGs) and the RNA-seq data were obtained from the TARGET database. ConsensusClusterPlus package was applied for the various subtypes based on the significant prognostic factors. Subsequently, the limma R package performed the Lasso analysis for a RiskScore model. The survminer package conducted Kaplan-Meier (KM) analysis, and the timeROC package was used for the classifier efficiency. In addition, the ssGSEA method and MCPcounter performed the immune infiltration analysis. Finally, the expression of the selected key genes, as well as their migration and invasion capabilities, were evaluated through PCR, wound healing, and transwell assays, respectively.

High GRG score was associated with poor prognosis. Unsupervised clustering based on prognostic GRGs identified two subtypes (C1/C2), with C1 showing worse outcomes. A prognostic RiskScore model comprising CORT, LPAR5, CEBPA, MYH10, and MAGEA11 was constructed from subtype-specific differentially expressed genes. The model effectively stratified patients into high- and low-risk groups in both training and validation cohorts, with high-risk patients exhibiting significantly shorter survival. RiskScore is an independent prognostic factor, with lower infiltration levels of cells such as macrophages and NK cells observed in patients within the high-risk group. In external immunotherapy cohorts, high-risk patients had poorer survival and treatment response. Functionally, silencing the key model gene CORT impaired osteosarcoma cell migration and invasion in vitro.

We developed a useful risk model and this study provided new insights for OS therapy.

论文信息

作者
Li X、Yang Z、Gu X、Song Y、Sun J、Ma F
第一作者单位
Department of Orthopedics, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.China
通讯作者单位
Department of Integrated Traditional and Western Medicine, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China. Godlovehorse@163.com.China
文献类型
验证性研究
期刊
European journal of medical research2026 Jan 5
原文标识
PubMed 41491534 · DOI 10.1186/s40001-025-03744-4